| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Monte Rosa Therapeutics (NASDAQ:GLUE) through any online brokerage.
Other companies in Monte Rosa Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Monte Rosa Therapeutics has a consensus price target of $26.13.
The stock price for Monte Rosa Therapeutics (NASDAQ: GLUE) is $11.19 last updated October 21, 2026 at 7:30 PM EDT.
There are no upcoming dividends for Monte Rosa Therapeutics.
Monte Rosa Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Monte Rosa Therapeutics.
Monte Rosa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
